Breaking News Instant updates and real-time market news.

TIF

Tiffany

, UNH

UnitedHealth

09:16
11/29/16
11/29
09:16
11/29/16
09:16

On The Fly: Pre-market Movers

HIGHER: CytRx (CYTR), up 34% after the company said its pivotal Phase 3 clinical trial demonstrated a statistically significant improvement in progression-free survival between aldoxorubicin and investigator's choice therapy in 246 patients with leiomyosarcoma and liposarcoma... Momenta Pharmaceuticals (MNTA), up 6% after a confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA candidate developed in collaboration with Shire's (SHPG) Baxalta, met its primary endpoint... TiVo (TIVO), up 6.75% after announcing it signed a product agreement and a separate intellectual property agreement with Netflix (NFLX)... UnitedHealth (UNH), up 3.4% after the company backed its fiscal 2016 guidance and provided better than expected guidance for fiscal 2017. UP AFTER EARNINGS: Tiffany (TIF), up 5.5%... Thor Industries (THO), up 10%. LOWER: Nivalis Therapeutics (NVLS), down 54% after the company announced that its Phase 2 trial evaluating the efficacy and safety of cavosonstat in adult patients with cystic fibrosis did not meet its primary endpoint... Amicus Therapeutics (FOLD), down 24% after ruling out accelerated approval for its migalastat product and confirming the need for additional data following its consultation with the FDA... AK Steel (AKS), down 5% after being downgraded to Neutral from Outperform at Macquarie... U.S. Steel (X), down 5% after being downgraded to Hold from Buy at Argus. DOWN AFTER EARNINGS: Shoe Carnival (SCVL), down 15%. Mallinckrodt (MNK), down 1%.

TIF

Tiffany

UNH

UnitedHealth

TIVO

TiVo

$20.75

0.05 (0.24%)

NFLX

Netflix

$116.93

-0.48 (-0.41%)

CYTR

CytRx

$0.56

-0.0079 (-1.40%)

NVLS

Nivalis Therapeutics

$6.25

-0.03 (-0.48%)

FOLD

Amicus

$8.32

-0.58 (-6.52%)

AKS

AK Steel

X

U.S. Steel

SCVL

Shoe Carnival

$30.27

-1.18 (-3.75%)

MNK

Mallinckrodt

MNTA

Momenta

$13.90

-0.25 (-1.77%)

SHPG

Shire

$174.84

-0.39 (-0.22%)

THO

Thor Industries

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 29

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 05

    Dec

  • 14

    Dec

  • 09

    Jan

TIF Tiffany

11/23/16
OPCO
11/23/16
NO CHANGE
Target $87
OPCO
Outperform
Tiffany price target raised to $87 from $80 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Tiffany to $87 from $80 ahead of results. While the analyst is concerned that a still challenged sales backdrop and higher expenses could weigh on results, longer term he is increasingly optimistic that internal merchandising and marketing efforts have the potential to fuel improved results, particularly as macro pressures potentially subside. Nagel reiterates an Outperform rating on the shares.
11/14/16
JEFF
11/14/16
NO CHANGE
Target $100
JEFF
Buy
Tiffany price target raised to $100 from $85 at Jefferies
Jefferies analyst Randal Konik raised his price target for Tiffany to $100 saying the company has a strong positioning in a growing market. Fashion jewelry fundamentals are improving while tourism headwinds are abating, Konik tells investors in a research note. The analyst reiterates a Buy rating on the shares.
11/17/16
JEFF
11/17/16
NO CHANGE
Target $100
JEFF
Buy
Jefferies sees 'robust' traffic at Tiffany flagship store amid Trump protests
After spending three days monitoring Tiffany's 5th Avenue flagship store in Manhattan to gauge traffic patterns and any Trump Tower protest related issues, Jefferies analyst Randal Konik concluded the store's traffic "was robust, not weak." Street police activity was high but didn't inhibit entrance to the store, Konik tells investors in a research note titled "5th Ave Flagship Store Checks Over Three Days Show 'Huuuuge' Strength." He believes investors are concerned that protests surrounding Trump Tower and high security will disrupt Tiffany's 5th Avenue store business. Konik keeps a Buy rating on Tiffany with a $100 price target.
11/11/16
11/11/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Equal Weight from Underweight at Barclays with analyst Kannan Venkateshwar saying ESPN is "de-risked" going into 2017 after management quantified the impact of the new NBA contract. 2. Aetna (AET) and Humana (HUM) were upgraded to Outperform from Neutral at Credit Suisse, while the firm upgraded WellCare (WCG) to Neutral from Underperform. 3. Anadarko (APC) and EOG Resources (EOG) were upgraded to Buy from Neutral at Guggenheim. 4. Tiffany (TIF) upgraded to Outperform from Market Perform at Cowen with analyst Oliver Chen saying he believes the luxury market is coming back and Tiffany is well positioned and a trusted brand. 5. Vornado (VNO) upgraded to Buy from Neutral at BofA/Merrill with analyst James Feldman saying he believes the decision to spin DC and partner with JBG will allow management to focus on the New York City platform and notes the Penn Plaza corridor is rapidly improving. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
UNH UnitedHealth

10/19/16
LEER
10/19/16
NO CHANGE
Target $175
LEER
Outperform
UnitedHealth price target raised to $175 from $165 at Leerink
Leerink analyst Ana Gupte raised her price target for UnitedHealth to $175 from $165 after the company reported a "solid beat and raise" Q3, giving her more confidence in the strength of the company's diversified platform and execution while also offering positive read-across for Commercial Fully Insured & Individual fundamentals to the rest of the group. The analyst reiterates an Outperform rating on the shares.
11/09/16
MZHO
11/09/16
DOWNGRADE
MZHO
Neutral
UnitedHealth downgraded to Neutral from Buy at Mizuho
11/09/16
MZHO
11/09/16
DOWNGRADE
Target $135
MZHO
Neutral
UnitedHealth downgraded to Neutral on Republican win at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded UnitedHealth to Neutral from Buy citing Donald Trump's election and the move to a GOP Congress. Following the election results, Skolnick sees an "extreme risk" for the ACA to be repealed and replaced and for the loss of the Medicaid expansion, both of which she notes have been primary drivers of results for hospitals and health plans. She cut her price target on the stock to $135 from $169.
11/09/16
BERN
11/09/16
NO CHANGE
BERN
Health insurers to see multiple catalysts from Trump presidency, says Bernstein
Bernstein analyst Lance Wilkes says that "repealing and replacing Obamacare will be Trump's primary focus." The analyst expects health insurers to benefit from from the repeal of ACA taxes and the elimination of requirements to spend a certain percentage of revenue on medical costs. Wilkes expects Anthem (ANTM) and Blue Cross/Blue Shield providers to benefit from the elimination of public exchanges and broad coverage requirements. Other health insurers include Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
TIVO TiVo
$20.75

0.05 (0.24%)

10/31/16
JPMS
10/31/16
NO CHANGE
JPMS
Overweight
TiVo deal renewal shows IP portfolio strong, says JPMorgan
JPMorgan analyst Sterling Auty believes the worldwide multi-year renewal license with Panasonic (PCRFY) is another sign that TiVo's intellectual property portfolio remains strong. TiVo is positioned to land the last remaining pay TV operator out of contract in the U.S., Comcast (CMCSA), Auty tells investors in a research note. He keeps an Overweighrt rating on TiVo.
06/01/16
MKMP
06/01/16
DOWNGRADE
MKMP
Neutral
TiVo downgraded to Neutral from Buy at MKM Partners
05/13/16
RILY
05/13/16
NO CHANGE
Target $29
RILY
Buy
Rovi added to Focus List at B. Riley
B. Riley analyst Eric Wold added Rovi (ROVI) to his firm's Focus List saying a near-term resolution with DISH/EchoStar should "provide a boost" to 2016 guidance. This catalyst combined with the accretive acquisition of TiVo could drive shares meaningfully higher in the coming months, Wold tells investors in a research note. He has a Buy rating on Rovi with a $29 price target.
11/29/16
JPMS
11/29/16
NO CHANGE
Target $34
JPMS
Overweight
TiVo agreement with Netflix a positive, says JPMorgan
JPMorgan analyst Sterling Auty views TiVo's (TIVO) licensing agreement with Netflix (NFLX) as a positive for the company. The deal adds incremental revenue and eliminates the legal costs associated with Netflix litigation, Auty tells investors in a research note. He also believes the contract demonstrates the strength of TiVo's patent portfolio. The analyst keeps an Overweight rating on the shares with a $34 price target.
NFLX Netflix
$116.93

-0.48 (-0.41%)

11/21/16
11/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Brean Capital. 2. Allergan (AGN) initiated with a Market Perform at William Blair. 3. Myovant Sciences (MYOV) was initiated with an Overweight at Barclays, an Outperform at JMP Securities, an Outperform at Baird, a Buy at Citi, and an Outperform at Cowen. 4. RA Pharmaceuticals (RARX) was initiated with a Buy at Jefferies, a Buy at SunTrust, and an Outperform at Credit Suisse. 5. ZTO Express (ZTO) was initiated with a Buy ratings at Citi and Goldman and an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/23/16
OPCO
11/23/16
NO CHANGE
OPCO
Facebook, Amazon.com most attractive on post-election pullback, says Oppenheimer
Oppenheimer analyst Jason Helfstein notes that there has been a rotation into industrial and financial stocks post-election, at the expense of multinational technology stocks. However, he sees some potential positive catalysts for "FANG" names, namely Facebook (FB), Amazon.com (AMZN), Netflix (NFLX) and Google (GOOG; GOOGL), with the first two looking the most attractive at current levels. The analyst points out that Facebook's potential positive catalysts include faster than expected ad monetization driven by "Video First" strategy, Instagram engagement and Dynamic Product Ads. As for Amazon, he expects stable consumer spending to support a strong holiday shopping season.
11/21/16
BMUR
11/21/16
INITIATION
Target $145
BMUR
Buy
Netflix initiated with a Buy at Brean Capital
Brean Capital analyst Alan Gould started Netflix with a Buy rating and $145 price target. The company has created an "unstoppable lead" in the internet TV business and is positioned to dominate the business long term, Gould tells investors in a research note. He believes Netflix over the next 15 years can attract 300M global subscribers and generate over $25 of earnings per share. The stock closed Friday up 18c to $115.21.
CYTR CytRx
$0.56

-0.0079 (-1.40%)

01/07/16
JEFF
01/07/16
INITIATION
Target $3
JEFF
Hold
CytRx initiated with a Hold at Jefferies
Jefferies analyst Chris Howerton started CytRx with a Hold rating and $3 price target. The stock is fairly valued given the opportunity for Aldoxorubicin in 2nd-line soft tissue sarcoma, the analyst tells investors in a research note.
01/07/16
01/07/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Agilent (A) initiated with a Hold at Deutsche Bank... Alexion (ALXN) initiated with a Buy at SunTrust... Alibaba (BABA) initiated with an Outperform at Baird... Bruker (BRKR) initiated with a Market Perform at Avondale... Care Capital Properties (CCP) initiated with a Neutral at Mizuho... Celgene (CELG) initiated with a Buy at SunTrust... Cepheid (CPHD) initiated with an Outperform at Avondale... Community Bank System (CBU) initiated with a Neutral at Piper Jaffray... CytRx (CYTR) initiated with a Hold at Jefferies... Del Taco (TACO) initiated with a Buy (yesterday) at BTIG... Depomed (DEPO) initiated with a Neutral at Mizuho... Ensco (ESV) initiated with an Equal Weight at Stephens... FCB Financial (FCB) initiated with a Buy at Gabelli... FactSet (FDS) initiated with a Hold at Evercore ISI... Fluidigm (FLDM) initiated with a Buy at Deutsche Bank... GTT Communications (GTT) initiated with an Overweight at Stephens... IBERIABANK (IBKC) initiated with a Neutral at Piper Jaffray... Illumina (ILMN) initiated with a Hold at Deutsche Bank... InspireMD (NSPR) initiated with a Buy at Rodman & Renshaw... Johnson Controls (JCI) initiated with an Outperform at Oppenheimer... McGraw Hill Financial (MHFI) initiated with a Buy at Evercore ISI... Moody's (MCO) initiated with a Hold at Evercore ISI... Myriad Genetics (MYGN) initiated with a Buy at Deutsche Bank... NBT Bancorp (NBTB) initiated with a Neutral at Piper Jaffray... Omnicell (OMCL) initiated with a Buy at Benchmark... Ophthotech (OPHT) initiated with a Buy at SunTrust... Paycom (PAYC) initiated with an Outperform at Baird... Paylocity (PCTY) initiated with an Outperform at Baird... PerkinElmer (PKI) initiated with a Hold at Deutsche Bank... Rowan Companies (RDC) initiated with an Equal Weight at Stephens... Shopify (SHOP) initiated with an Outperform at Baird... Syngenta (SYT) initiated with a Neutral at Macquarie... Thermo Fisher (TMO) initiated with a Buy at Deutsche Bank... Trovagene (TROV) initiated with a Market Perform at Avondale... UTi Worldwide (UTIW) to host special shareholder meeting... Waters (WAT) initiated with a Hold at Deutsche Bank... Wayfair (W) initiated with a Neutral at Baird... Willis Towers Watson (WLTW) initiated with an Underweight at JPMorgan.
07/12/16
JEFF
07/12/16
NO CHANGE
Target $0.75
JEFF
Hold
CytRx price target lowered to 75c from $2.50 at Jefferies
Jefferies analyst Chris Howerton cut his price target for CytRx to 75c from $2.50 after removing aldoxorubicin from his model following today's study failure. The analyst does not see a path forward for the drug in soft tissue sarcomas or any other indications. He keeps a Hold rating on the name. FBR Capital analyst Christopher James said this morning that despite missing on the endpoint, aldoxorubicin demonstrated clear clinical activity, with an objective response rate nearly double the rate observed within the comparator arm. CytRx is down 62% to 95c in late morning trading.
07/12/16
FBRC
07/12/16
NO CHANGE
Target $3
FBRC
Outperform
CytRx price target lowered to $3 from $8 at FBR Capital
FBR Capital analyst Christopher James cut his price target for CytRx to $3 after the company's Phase III study with aldoxorubicin in patients with relapsed or refractory soft-tissue sarcoma was unable to meet its primary endpoint. Despite missing on the endpoint, aldoxorubicin demonstrated clear clinical activity, with an objective response rate nearly double the rate observed within the comparator arm, James tells investors in a research note. He keeps an Outperform rating on CytRx. In pre-market trading, the stock is down 69% to 77c.
NVLS Nivalis Therapeutics
$6.25

-0.03 (-0.48%)

11/29/16
11/29/16
DOWNGRADE
Target $3

Neutral
Nivalis Therapeutics downgraded to Neutral at Baird
As previously reported, Baird analyst Brian Skorney downgraded Nivalis Therapeutics to Neutral from Outperform following the clinical trial failure of its flagship proof-of-concept study of its drug for cystic fibrosis. Skorney lowered his price target to $3 from $29 on Nivalis Therapeutics shares. Nivalis shares have also been downgraded by at least three other firms this morning.
11/29/16
COWN
11/29/16
DOWNGRADE
COWN
Market Perform
Nivalis Therapeutics downgraded to Market Perform at Cowen
As reported previously, Cowen analyst Phil Nadeau downgraded Nivalis Therapeutics to Market Perform from Outperform. The analyst said its proof-of-concept Phase 2 trial for cystic fibrosis demonstrated no benefits for lung function or sweat chloride, two established measures of activity. The drug was the company's primary asset, Nadeau noted.
11/29/16
STFL
11/29/16
DOWNGRADE
STFL
Hold
Nivalis Therapeutics downgraded on lack of drug efficacy at Stifel
As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.
11/29/16
BARD
11/29/16
DOWNGRADE
BARD
Neutral
Nivalis Therapeutics downgraded to Neutral from Outperform at Baird
FOLD Amicus
$8.32

-0.58 (-6.52%)

11/29/16
COWN
11/29/16
NO CHANGE
Target $12
COWN
Outperform
Amicus price target lowered to $12 from $15 at Cowen
Cowen analyst Ritu Baral lowered her price target on Amicus to $12 from $15 after the FDA told the company it could not file the Galafold NDA with current data and that data from a new trial is expected in 2019. Baral maintained her Outperform rating on Amicus, stating that the planned GI trial has a good chance of success.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
07/20/16
JPMS
07/20/16
NO CHANGE
Target $13
JPMS
Overweight
Amicus risk/reward 'compelling' at current levels, says JPMorgan
JPMorgan analyst Anupam Rama views the risk/reward for shares of Amicus Therapeutics at current levels as "compelling." After declining 39% year-to-date, Amicus is essentially only pricing in outside the U.S. Galafold sales in Fabry disease plus cash, Rama tells investors in a research note. Very little credit is being given to the company's U.S. migalastat, Zorblisa or the Pompe program, which all have events in the second half of 2016, the analyst contends. Rama thinks only one of the three need to hit for the stock to trade "materially higher," with upside ranging from 20%-100%-plus on a single success, and "meaningfully more upside" potential on multiple positive updates. Rama reiterates an Overweight rating on Amicus with a $13 price target.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
AKS AK Steel

11/14/16
11/14/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lockheed Martin (LMT) upgraded to Buy from Hold at Stifel with analyst Joseph DeNardi saying he is pleased with the company's comments regarding its 2018 free cash flow outlook, and he thinks that it could benefit from increased defense spending in the wake of the election results. 2. Philip Morris (PM) upgraded to Buy from Outperform at CLSA with analyst Michael Levy citing the recent pullback for his rating change and said he sees the company adding to its buyback. 3. Citi (C) upgraded to Overweight from Equal Weight at Morgan Stanley with analysts led by Betsy Graseck saying the Republican sweep is positive for all financial stocks due to increased growth, higher rates, lower taxes, and less regulation. 4. U.S. Steel (X) and AK Steel (AKS) upgraded to Overweight from Equal Weight at Morgan Stanley. 5. L Brands (LB), Kohl's (KSS), and Chico's(CHS) were upgraded to Buy from Neutral at Citi, while Chico's was also upgraded to Outperform from Peer Perform at Wolfe Research. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/16
MSCO
11/14/16
UPGRADE
MSCO
Overweight
AK Steel upgraded to Overweight from Equal Weight at Morgan Stanley
11/14/16
MSCO
11/14/16
UPGRADE
Target $11
MSCO
Overweight
AK Steel upgraded on upside to infrastructure cycle at Morgan Stanley
Morgan Stanley analyst Evan Kurtz upgraded AK Steel to Overweight from Equal Weight and raised its price target to $11 from $5. The analyst believes the Trump victory has led to the first "credible long-term investment case" for steel equities for the first time in a decade and expects Trump's proposals for infrastructure spending and trade protection to add to demand and curb import supply. Kurtz expects AK Steel to benefit from increased flat-rolled steel demand, ongoing cost savings, and leverage to an infrastructure upcycle.
11/29/16
MACQ
11/29/16
DOWNGRADE
Target $9
MACQ
Neutral
AK Steel downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Aldo Mazzaferro downgraded AK Steel to Neutral and raised its price target to $9 from $6.80 saying valuation more than discounts what he is expecting for earnings.
X U.S. Steel

11/21/16
11/21/16
DOWNGRADE

Neutral
Follow-up: U.S. Steel downgraded on valuation, slowing auto growth at Rosenblatt
As previously reported, Rosenblatt downgraded U.S. Steel to Neutral from Buy. Analyst Chris Olin said shares appear fairly valued given recent share strength and reduced demand visibility and decelerating automotive growth.
11/29/16
ARGS
11/29/16
DOWNGRADE
ARGS
Hold
U.S. Steel downgraded to Hold from Buy at Argus
11/21/16
RSBL
11/21/16
DOWNGRADE
RSBL
Neutral
U.S. Steel downgraded to Neutral from Buy at Rosenblatt
SCVL Shoe Carnival
$30.27

-1.18 (-3.75%)

09/15/16
SUSQ
09/15/16
INITIATION
Target $27
SUSQ
Neutral
Shoe Carnival initiated with a Neutral at Susquehanna
Susquehanna analyst Sam Poser initiated Shoe Carnival with a Neutral and a $27 price target.
06/07/16
SIDC
06/07/16
INITIATION
Target $27
SIDC
Neutral
Shoe Carnival initiated with a Neutral at Sidoti
Target $27.
03/30/16
STPT
03/30/16
DOWNGRADE
STPT
Hold
Shoe Carnival downgraded to Hold from Buy at Standpoint Research
09/15/16
SUSQ
09/15/16
INITIATION
Target $27
SUSQ
Neutral
Shoe Carnival initiated with a Neutral at Susquehanna
Target $27.
MNK Mallinckrodt

11/18/16
RAJA
11/18/16
INITIATION
Target $72
RAJA
Outperform
Mallinckrodt initiated with an Outperform and $72 price target at Raymond James
Raymond James analyst Elliot WIlbur initiated Mallinckrodt with an Outperform and a $72 price target saying negative sector sentiment combined with further allegations from short sellers have created a compelling entry point. Wilbur believes Mallinckrodt provides one of the most sustainable top and bottom line growth trajectories in specialty pharmaceuticals and notes Achar has only a 3% penetration rate of the total addressable market, giving it a long runway of growth.
11/17/16
WELS
11/17/16
NO CHANGE
WELS
Outperform
Mallinckrodt drop on short-seller report a buying opportunity, says Wells Fargo
Wells Fargo analyst David Maris said the 12% drop in Mallinckrodt on the heels of a new report from short-seller Citron Research presents a buying opportunity, as he believes the assertion that Acthar has no clinical data is incorrect. Maris noted the report came out during Mallinckrodt's quiet period, which is something that had previously happened with a prior Citron report on the company, but the company tells him that the CEO's previous answer to a question regarding Acthar's exposure to Medicaid and Medicare was accurate. Maris keeps an Outperform rating on Mallinckrodt shares.
11/21/16
UBSW
11/21/16
NO CHANGE
Target $92
UBSW
Buy
Mallinckrodt weakness does not make sense, says UBS
UBS analyst Marc Goodman attended Mallinckrodt investors meetings and came away believing investors misunderstand the company story. The analyst said the company's Acthar drug, which has come under fire, has little relevance to the overall story. Goodman said the company has focused on enhancing clinical and health-economics data to help support better coverage and it is working. He said its emerging pipeline is under-appreciated. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
11/17/16
RAJA
11/17/16
INITIATION
Target $72
RAJA
Outperform
Mallinckrodt initiated with an Outperform at Raymond James
Raymond James initiated Mallinckrodt with an Outperform and a $72 price target.
MNTA Momenta
$13.90

-0.25 (-1.77%)

09/07/16
MAXM
09/07/16
DOWNGRADE
MAXM
Sell
Momenta downgraded to Sell from Hold at Maxim
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
11/22/16
AGIS
11/22/16
INITIATION
Target $15
AGIS
Hold
Momenta initiated with a Hold at Aegis
Aegis analyst Difei Yang iniatied Momenta with a Hold and a $15 price target.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
SHPG Shire
$174.84

-0.39 (-0.22%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
JPMorgan says Merrimack could fit as target for Shire
JPMorgan analyst Anupam Rama believes Merrimack Pharmaceuticals (MACK) could fit as a potential target for Shire (SHPG). The $1B deal size would be manageable, Rama tells investors in a research note after Ben Harrington's Betaville blog, citing sources, reported Friday that Shire is among the companies participating in Merrimack's strategic review process. Assuming a 40% premium to the intraday Merrimack share price, the deal would be 1% accretive in 2019 and 2% accretive in 2020, Rama estimates.
11/01/16
BTIG
11/01/16
NO CHANGE
Target $242
BTIG
Buy
Shire's recent weakness overdone, says BTIG
BTIG analyst Timothy Chiang believes the recent selloff in Shire is overdone and that weakness in the Hematology segment was impacted by the timing of large orders. The analyst maintains his Buy rating and $242 price target on Shire shares.
11/02/16
LEER
11/02/16
NO CHANGE
Target $198
LEER
Outperform
Shire price target lowered to $198 from $234 at Leerink
Following a modest Q3 miss, Leerink analyst Jason Gerberry lowered his price target for Shire to $198 from $234 to reflect a more conservative outlook on key franchises due to out-year competitive pressures. The analyst reiterates an Outperform rating on the stock as he believes concerns around pricing look overdone and shares are attractively valued.
THO Thor Industries

09/28/16
WLSD
09/28/16
UPGRADE
WLSD
Buy
Thor Industries upgraded to Buy from Gradually Accumulate at Wellington Shields
09/13/16
NRCS
09/13/16
UPGRADE
Target $95
NRCS
Buy
Thor Industries upgraded to Buy from Neutral at Northcoast
Northcoast analyst Seth Woolf upgraded Thor Industries to Buy with a $95 price target. The analyst said the recent move in shares still doesn't reflect full accretion of the Jayco acquisition nor the strategic benefits. Woolf believes that the Jayco deal gives the company the best product portfolio in the industry. This is particularly true as it relates to Thor's ability to ride the wave of younger consumers entering the channel via entry-level travel trailers, the analyst wrote.
08/19/16
WDLK
08/19/16
DOWNGRADE
Target $80
WDLK
Hold
Thor Industries downgraded to Hold from Buy at Wunderlich
Wunderlich analyst Rommel Dionisio downgraded Thor Industries to Hold citing the recent rally in the shares. The analyst keeps an $80 price target for the name.
07/29/16
RHCO
07/29/16
UPGRADE
RHCO
Buy
Thor Industries upgraded on multiple catalysts at SunTrust
As noted earlier, SunTrust upgraded Thor to Buy from Neutral. Analyst Michael Swartz predicts that the company will benefit from higher than expected accretion and synergies from its Jayco acquisition, as well as 20%-40% growth in industry volumes by 2020. Target $90.

TODAY'S FREE FLY STORIES

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 03

    Dec

  • 06

    Dec

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.